Twist Bioscience
TWST
$122.59
-7.22%
Twist Bioscience is a synthetic biology company that has industrialized DNA synthesis through a proprietary semiconductor-based platform that writes DNA on silicon rather than traditional plastic plates, serving customers across NGS tools, synthetic genes, antibody discovery, and biopharma drug discovery in the Americas, EMEA, and APAC. The company occupies a distinctive position as a vertically integrated platform disruptor in the life-science tools space, competing on throughput, cost, and quality against legacy oligo and gene synthesis providers while increasingly positioning itself as an AI-enabled data and discovery partner rather than a pure-play reagent supplier. The current investor narrative is dominated by Twist's participation in Eli Lilly's TuneLab AI platform, which the market has interpreted as third-party validation of its proprietary sequence and antibody data assets, and that catalyst has driven an extraordinary re-rating of the shares over the past year. At the same time, debate is intensifying around whether the roughly 23% revenue growth and improving gross margins can justify a valuation that has expanded far faster than the underlying business, with the stock's violent post-September drawdown underscoring how much optimism is now embedded in the price.…
TWST
Twist Bioscience
$122.59
Related headlines
Investment Opinion: Should I buy TWST Today?
Rating: Hold (accumulate only on further weakness). The core thesis is that Twist is a genuinely differentiated synthetic-biology platform — 23.24% revenue growth, gross margin up roughly 760bps to 52.76% since Q4 2024, and sequential FCF improvement to -$8.5 million — but at $135.34 the stock already discounts a successful conversion of the Lilly TuneLab narrative into disclosed, high-margin data revenue, leaving the risk/reward roughly balanced rather than compelling. The 9-Buy/3-Hold/1-Sell consensus (mean score 1.92) and $168.25 average target imply about 24.3% upside, which is real but modest relative to a beta of 2.222 and a -41.17% max drawdown.
Supporting evidence is mixed but leans constructive on operations and cautious on price. Revenue rose sequentially from $103.7 million to $110.7 million to $118.4 million across Q1-Q3 2026, annualizing to roughly $460 million against a $1.011 billion forward consensus — a bridge that requires more than doubling. Gross margin of 52.76% and a 3.64 current ratio with debt-to-equity of 0.29 confirm the platform economics and balance-sheet durability, while trailing FCF of -$93.1 million, a -29.6% net margin, and EV/Sales of 17.41x show how much future execution is embedded in the multiple. The $45-$215 analyst target spread (4.8x) against tightly clustered forward EPS ($0.891-$0.978) tells you the disagreement is entirely about terminal value, not near-term numbers.
The biggest risks that could invalidate this view are (1) TuneLab failing to convert into disclosed contract economics, which would force a re-rating toward tools-peer multiples, (2) forward revenue guidance falling below the $974 million low end of consensus, and (3) continued cash burn requiring equity issuance — cash fell from $185.4 million to $119.6 million year-over-year with $18.2 million of quarterly stock-based compensation. This Hold would upgrade to Buy on a pullback toward the $110-$120 support zone (roughly 30-35% upside to the average target) or on a disclosed Lilly data/discovery contract with quantified revenue; it would downgrade to Sell on a break below $120 that confirms a lower-high/lower-low sequence, or on gross margin slipping back below 50%. Valuation verdict: fairly valued to modestly rich on EV/Sales (17.41x) but at the low end of its own historical sales-multiple band (PS 4.47x versus 54.2x in Q3 2026), meaning the de-rating has largely happened but offers little cushion if growth disappoints.
Sign up to view all
TWST 12-Month Price Forecast
The forward view is genuinely two-sided: operating momentum is real and improving (sequential revenue growth, ~760bps of gross margin expansion, FCF burn narrowing to -$8.5 million), but the price already embeds a successful conversion of the Lilly TuneLab narrative into a high-margin data/discovery business, and the 17.41x EV/Sales multiple leaves no room for a guidance miss. The sell-side is constructive on balance — 9 of 12 analysts rate Buy with a $168.25 average target — yet the 4.8x spread between the $45 and $215 targets reveals that conviction on terminal value is very low, which is a recipe for violent reactions to any news. With beta at 2.222 and a -41.17% max drawdown already observed, position sizing should assume 40%+ peak-to-trough swings are routine. I would upgrade to bullish on a disclosed Lilly contract with quantified revenue, gross margin above 55%, or a pullback toward the $110-$120 support zone that restores a 40%+ upside to the average target; I would downgrade to bearish on a break below $120, a forward revenue guide below $974 million, or gross margin slipping back under 50%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Twist Bioscience's 12-month outlook, with a consensus price target around $168.25 and implied upside of +37.3% versus the current price.
Average Target
$168.25
13 analysts
Implied Upside
+37.3%
vs. current price
Analyst Count
13
covering this stock
Price Range
$45 - $215
Analyst target range
Coverage is solid for a company of this size, with 12 analysts publishing ratings: 9 Buy, 3 Hold, and 1 Sell, producing a consensus recommendation of "buy" and a mean recommendation score of 1.92 (where 1.0 is a strong buy). The average target price is $168.25, which implies roughly 24.3% upside from the current $135.34, and the consensus clearly leans bullish despite the stock's recent 15.3% monthly decline. Institutional ratings activity over the past several months has been uniformly constructive — TD Cowen, Canaccord Genuity, Barclays, Guggenheim, Leerink Partners, Piper Sandler, and Baird have all reiterated Buy/Outperform/Overweight ratings between July and October 2026, with only BWS Financial maintaining a Sell — suggesting the sell-side views the drawdown as an opportunity rather than a deterioration in fundamentals.\n\nThe target range is exceptionally wide, from a low of $45.00 to a high of $215.00 — a 4.8x spread that signals very low conviction on terminal value and enormous dispersion in assumptions about the AI/discovery opportunity. The $215 high target effectively assumes the Lilly TuneLab partnership scales into a durable, high-margin data and discovery revenue stream with multiple expansion back toward prior peaks, while the $45 low target discounts a return to pure-tools economics with continued cash burn and competitive pressure on synthetic DNA pricing. The forward EPS consensus of $0.935 (range $0.891-$0.978) and revenue consensus of $1.011 billion (range $974 million-$1.046 billion) are tightly clustered, meaning analysts agree on near-term numbers but disagree violently on what those numbers are worth — a classic setup for elevated volatility and sharp reactions to any guidance revision.
Drowning in data?
Find the real signal!
Bulls vs Bears: TWST Investment Factors
The bull case rests on tangible operating progress — 23.24% revenue growth, a 52.76% gross margin up roughly 760bps from Q4 2024, sequential FCF improvement to -$8.5 million, and a fortress balance sheet with a 3.64 current ratio — amplified by the Lilly TuneLab validation and a 9-Buy/3-Hold/1-Sell sell-side consensus with a $168.25 average target. The bear case is not about the business deteriorating but about price: EV/Sales of 17.41x, a $1.011 billion forward revenue consensus versus a ~$460 million run-rate, -$35.1 million of quarterly net loss, and a 4.8x spread between the $45 and $215 analyst targets. On balance the evidence currently favors the bulls on fundamentals but the bears on risk/reward, because the stock has already re-rated 347% in a year and sits 38% below its October high with momentum decisively negative. The single most important tension is whether the Lilly TuneLab relationship converts into disclosed, high-margin data/discovery revenue — if it does, the forward revenue bridge becomes credible and the multiple is defensible; if it remains a headline without contract economics, the stock is a tools company trading at a discovery-platform price.
Bullish
- Revenue re-accelerating sequentially: Q3 2026 revenue of $118.4 million grew 23.24% year-over-year and rose sequentially from $110.7 million in Q2 and $103.7 million in Q1, a consistent cadence that annualizes to roughly $460 million. The two segments are now nearly balanced — NGS Tools at $61.8 million and Antibody Discovery at $56.6 million — meaning growth is no longer dependent on a single franchise.
- Gross margin expansion of ~760bps: Q3 2026 gross margin reached 52.76%, up from 51.59% in Q2 and 52.05% in Q1, and materially above the 45.13% recorded in Q4 2024. That roughly 760 basis point expansion over seven quarters demonstrates real operating leverage in the silicon-based synthesis platform rather than a one-off mix benefit.
- Lilly TuneLab validates data assets: Twist's participation in Eli Lilly's TuneLab AI platform has been read by the market as third-party validation of its proprietary sequence and antibody data, and it coincided with the stock's parabolic move from $54.39 in mid-May to $205.00 on October 5. If the partnership scales into a data/discovery revenue stream, it would carry structurally higher margins than reagent sales.
- Sell-side firmly constructive: Of 12 analysts, 9 rate Buy, 3 Hold and only 1 Sell, producing a consensus 'buy' and a mean score of 1.92. The average target of $168.25 implies roughly 24.3% upside from $135.34, and TD Cowen, Canaccord, Barclays, Guggenheim, Leerink, Piper Sandler and Baird all reiterated constructive ratings between July and October 2026.
Bearish
- Valuation still demands a step-change: EV/Sales of 17.41x and price-to-book of 3.56x are rich for a company with a -20.6% net margin, and the forward consensus revenue of $1.011 billion implies more than double the current ~$460 million annualized run-rate. The market is paying today for revenue that does not yet exist, which leaves little room for guidance disappointment.
- Losses remain large and persistent: Q3 2026 net income was -$35.1 million (-29.6% net margin) and operating income -$36.3 million (-30.6% margin). Operating expenses of $98.7 million against $62.5 million of gross profit means Twist still spends about $1.58 in opex for every dollar of gross profit — a ratio that must fall sharply for profitability to arrive.
- Extreme volatility and blown-off momentum: Beta of 2.222 and a max drawdown of -41.17% mean 40%+ peak-to-trough swings are routine. The stock is down 15.3% over the past month with 1-month relative strength of -12.0 points versus SPY, even as the 1-year relative strength is +334.9 points — a classic parabolic-gain/negative-slope divergence.
- Analyst targets imply near-zero conviction: The target range spans $45.00 to $215.00, a 4.8x spread, despite tightly clustered forward EPS ($0.891-$0.978) and revenue ($974 million-$1.046 billion) estimates. Analysts agree on near-term numbers but disagree violently on terminal value, a setup for sharp reactions to any guidance revision.
TWST Technical Analysis
Twist is in a powerful but extraordinarily volatile uptrend: the stock is up 347.1% over the past year and 317.8% year-to-date, closing at $135.34 on 2026-11-09. That places the price at roughly 57% of its 52-week range of $23.30 to $219.71, meaning the stock sits in the upper-middle of its band but a full 38% below the October high — a positioning that reflects strong residual momentum but also a market that has already de-risked a substantial portion of the prior euphoria. The 52-week low of $23.30 versus the current price implies a nearly 6x move off the bottom, a magnitude that historically invites profit-taking and sharp mean-reversion episodes.\n\nShort-term momentum has decisively decelerated and now diverges from the longer-term trend. The stock is down 15.3% over the past month versus a 9.9% gain over three months and a 148.8% gain over six months, and its 1-month relative strength versus SPY is -12.0 points even as 1-year relative strength is +334.9 points. This divergence — parabolic annual gains colliding with a negative monthly slope — is the classic signature of a blow-off top in the process of digesting, and the 12.0% single-day rebound on 2026-11-09 from $120.79 to $135.34 shows buyers are still defending the name aggressively. Volume of roughly 1.67 million shares on that session, combined with a short ratio of 3.22 days to cover, suggests the bounce may have been amplified by short covering rather than fresh institutional accumulation.\n\nKey technical levels are unusually wide because of the stock's volatility. Support sits in the $120-$129 zone established by the early-November lows, with secondary support at the October trough near $132.75 and the 52-week floor far below at $23.30; resistance is defined by the October 5 peak of $205.00 and the 52-week high of $219.71. A decisive break above $205 would signal a resumption of the primary uptrend and likely force short covering, while a loss of $120 would confirm a lower-high/lower-low sequence and open the door to a retest of the $100 area. With a beta of 2.222, Twist is more than twice as volatile as the S&P 500, and a maximum drawdown of -41.17% within the observed window means position sizing must assume 40%+ peak-to-trough swings are routine rather than exceptional.
Beta
2.22
2.22x market volatility
Max Drawdown
-41.2%
Largest decline past year
52-Week Range
$23-$220
Price range past year
Annual Return
+291.4%
Cumulative gain past year
| Period | TWST Return | S&P 500 |
|---|---|---|
| 1m | -19.3% | -2.4% |
| 3m | -2.2% | -2.3% |
| 6m | +149.3% | +2.8% |
| 1y | +291.4% | +11.3% |
| ytd | +278.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TWST Fundamental Analysis
Revenue is growing briskly and, importantly, re-accelerating on a sequential basis. Fiscal Q3 2026 (quarter ended 2026-06-30) revenue was $118.4 million, up 23.24% year-over-year, versus $110.7 million in Q2 2026 and $103.7 million in Q1 2026 — a consistent sequential cadence that annualizes to roughly $460 million. Segment disclosure shows NGS Tools at $61.8 million and Antibody Discovery at $56.6 million, meaning the two pillars are now nearly balanced and the discovery business is contributing a larger share of incremental growth than the legacy synthetic biology franchise. Consensus estimates revenue of approximately $1.011 billion for the forward period, which implies a step-change well above the current run-rate and is the single most important assumption embedded in the stock.\n\nThe company remains unprofitable, but the margin trajectory is clearly improving. Q3 2026 gross margin was 52.76%, up from 51.59% in Q2 2026 and 52.05% in Q1 2026, and materially above the 45.13% recorded in Q4 2024 — a roughly 760 basis point expansion over seven quarters that reflects operating leverage in the silicon-based synthesis platform. Net income was -$35.1 million in Q3 2026 (a -29.6% net margin) and operating income was -$36.3 million (-30.6% operating margin), with the loss narrowing from -$44.0 million in Q2 2026 and -$30.5 million in Q1 2026; the Q2 figure was distorted by a -$5.3 million other-expense swing, so the underlying trend is one of gradual loss compression. Research and development of $18.0 million and SG&A of $80.7 million together consumed $98.7 million against $62.5 million of gross profit, meaning the company still spends roughly $1.58 in operating expense for every dollar of gross profit — a ratio that must fall for profitability to arrive.\n\nThe balance sheet is a genuine strength even as cash burn persists. The current ratio is 3.64, debt-to-equity is a modest 0.29, and cash stood at $119.6 million at quarter-end, down from $185.4 million a year earlier. Free cash flow is deeply negative at -$93.1 million on a trailing-twelve-month basis, with Q3 2026 FCF of -$8.5 million, Q2 of -$25.5 million, and Q1 of -$34.8 million — a sequential improvement that is encouraging but still leaves the company dependent on capital markets. Stock-based compensation of $18.2 million in Q3 alone is a meaningful non-cash drag, and ROE of -16.4% and ROA of -13.1% confirm that the equity base is not yet generating a return; the cash pile covers roughly 14 quarters of current burn, so financing risk is not imminent but dilution remains a live consideration.
Quarterly Revenue
$118376000.0B
2026-06
Revenue YoY Growth
+23.2%
YoY Comparison
Gross Margin
52.8%
Latest Quarter
Free Cash Flow
$-93123000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TWST Overvalued?
Because Twist's trailing net income is negative (EPS of -$0.05 and a trailing PE of -21.6x), the PE ratio is not a meaningful anchor, and the forward PE of -338.3x is equally unusable given that consensus profitability remains a forecast rather than a fact. I therefore lead with the price-to-sales ratio of 4.47x and the EV/Sales multiple of 17.41x, which are the appropriate metrics for a high-growth, pre-profit synthetic biology platform; the wide gap between the 4.47x PS and 17.41x EV/Sales reflects differing revenue bases in the calculation and warrants caution in relying on either in isolation. The forward EPS estimate of $0.935 against a trailing loss implies the market expects a swing to profitability within roughly a year, which is the central valuation bet.\n\nOn a peer basis, a PS of 4.47x is not obviously expensive for a life-science tools company growing revenue at 23% with 52.7% gross margins, and it sits well below the company's own historical norms. However, the EV/Sales of 17.41x and price-to-book of 3.56x paint a richer picture, and the negative EV/EBITDA of -31.4x and price-to-cash-flow of -35.3x confirm that cash-based multiples offer no support. The PEG ratio of 0.34 is superficially attractive but is computed off a depressed forward earnings base and should be treated skeptically; the more honest read is that Twist trades at a premium to mature tools peers on sales and at a steep discount to its own history, a combination that reflects both the growth premium and the de-rating already suffered.\n\nHistorical context is the most striking part of the valuation picture. The PS ratio was 54.2x as recently as Q3 2026 and 26.5x in Q2 2026, versus 4.47x today — a compression of more than 90% from the peak multiple, even as the share price rose. That apparent paradox is explained by the enormous revenue growth and the fact that the historical ratios are computed on different price and share-count bases; the practical takeaway is that Twist is now valued at the low end of its own multi-year sales-multiple band. Price-to-book of 3.56x compares with 14.4x in Q3 2026 and 6.4x in Q2 2026, reinforcing that the market has already repriced the equity sharply downward from its most exuberant levels, which cuts both ways: it limits further multiple compression but offers little cushion if growth disappoints.
PE
-21.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
-31.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the gap between the current run-rate and the consensus bridge. Q3 2026 revenue of $118.4 million annualizes to roughly $460 million, yet consensus forward revenue is $1.011 billion, so the company must more than double in the forecast period to meet expectations. Meanwhile net income was -$35.1 million (-29.6% margin), operating expenses of $98.7 million consumed $1.58 for every dollar of $62.5 million gross profit, trailing FCF is -$93.1 million, and cash fell from $185.4 million to $119.6 million year-over-year — roughly 14 quarters of runway at the current burn, with $18.2 million of quarterly stock-based compensation adding dilution risk. Revenue is also concentrated in two segments (NGS Tools $61.8 million, Antibody Discovery $56.6 million) and geographically in the Americas, so a slowdown in either pillar or a pricing war in synthetic DNA would hit the P&L quickly.
Market and competitive risks are dominated by valuation compression. EV/Sales of 17.41x and price-to-book of 3.56x offer no cash-flow support (EV/EBITDA -31.4x, price-to-cash-flow -35.3x), and the stock's beta of 2.222 means it moves more than twice the S&P 500 in either direction. The 4.8x spread between the $45 low and $215 high analyst target shows the market has no consensus on terminal value, so any headline that reframes the AI/discovery narrative — a competitor launching a comparable platform, a Lilly TuneLab milestone slipping, or a pricing push from legacy oligo suppliers — could compress the multiple violently. The recent news flow itself flags the risk: coverage of the Lilly partnership explicitly warned investors to 'brace for continued volatility,' and the stock's 15.3% one-month decline with -12.0 points of relative strength versus SPY shows the de-rating is already underway.
The worst-case scenario is a narrative reversal combined with a growth miss: TuneLab fails to convert into disclosed revenue, forward guidance is cut below the $974 million low end of consensus, and the market revalues Twist as a pure tools company at the $45 bear-case target. From $135.34 that is roughly -67%, and even a simple retest of the October 16 trough of $132.75 or the early-November low of $120.61 would cost 2%-11%. A full mean-reversion toward the 52-week low of $23.30 would be a -83% loss, extreme but not impossible given the stock rose nearly 6x off that level within twelve months and has already demonstrated a -41.17% max drawdown inside the observed window. Position sizing should assume a 40%-plus drawdown is a routine event rather than a tail risk.
FAQ
The most severe risk is valuation and narrative risk: at 17.41x EV/Sales with a -$35.1 million quarterly net loss, any failure to convert the Lilly TuneLab relationship into disclosed contract economics could force a re-rating toward the $45 bear-case target, roughly -67% from $135.34. Second is financial risk — trailing free cash flow of -$93.1 million, cash down from $185.4 million to $119.6 million year-over-year, and $18.2 million of quarterly stock-based compensation leave equity issuance and dilution as live threats, even with a 3.64 current ratio and 0.29 debt-to-equity. Third is execution risk on the growth bridge: revenue of $118.4 million annualizes to about $460 million versus a $1.011 billion forward consensus, so a guidance cut below the $974 million low end would be damaging. Fourth is market and competitive risk — a beta of 2.222, a -41.17% max drawdown, and the threat of pricing pressure from legacy oligo and gene synthesis suppliers, all amplified by a 4.8x spread between the $45 and $215 analyst targets that guarantees violent reactions to news.
The 12-month forecast splits into three scenarios. The base case carries 50% probability with a $150-$175 target range, assuming revenue tracks toward the $1.011 billion consensus, gross margin holds at or above 52%, and free cash flow burn keeps narrowing from -$8.5 million — landing near the $168.25 average analyst target. The bull case at 25% probability targets $190-$215, requiring the Lilly TuneLab relationship to convert into disclosed multi-year data and antibody-discovery revenue with margins in the high-50s, pushing the stock back toward the October 5 peak of $205 and the 52-week high of $219.71. The bear case at 25% probability spans $45-$120, triggered by a TuneLab milestone slip, guidance below the $974 million low end, or an equity raise, with a retest of the $23.30 52-week low possible in a full narrative unwind. The base case is most likely, and its key assumption is that near-term consensus numbers are met without a guidance cut.
TWST cannot be valued on earnings — trailing PE is -21.6x and forward PE is -338.3x because profitability remains a forecast rather than a fact — so sales-based metrics are the honest anchor. On that basis the picture is split: price-to-sales of 4.47x is not extreme for a life-science tools company growing revenue 23% with 52.7% gross margins, but EV/Sales of 17.41x and price-to-book of 3.56x are rich, and negative EV/EBITDA (-31.4x) and price-to-cash-flow (-35.3x) confirm there is no cash-flow support. Relative to its own history the stock has already de-rated sharply, with PS at 54.2x in Q3 2026 and 26.5x in Q2 2026 versus 4.47x today, and price-to-book down from 14.4x to 3.56x. The market is therefore paying a premium to mature tools peers but a steep discount to Twist's own peak multiples, implying it expects the revenue bridge to $1.011 billion to be delivered but no longer awards a speculative platform premium. The verdict is fairly valued to modestly rich, with little cushion if growth disappoints.
From a pure risk/reward standpoint, TWST is a reasonable but not compelling buy at $135.34. The upside case is anchored by a 9-Buy/3-Hold/1-Sell consensus and a $168.25 average target, implying roughly 24.3% upside, while the operating trend is genuinely improving — revenue up 23.24% year-over-year to $118.4 million and gross margin at 52.76%, about 760bps above Q4 2024. Against that, the stock trades at 17.41x EV/Sales on a run-rate that must more than double to reach the $1.011 billion forward consensus, and it has already fallen 15.3% in the past month with a beta of 2.222. The biggest downside risk is a re-rating toward the $45 bear-case target (about -67%) if the Lilly TuneLab narrative fails to convert into disclosed revenue. It is a good buy primarily for risk-tolerant growth investors who can size positions for 40%+ drawdowns, and it becomes materially more attractive on a pullback into the $110-$120 support zone or upon a disclosed Lilly contract with quantified economics.
TWST is structurally a long-term holding candidate but practically demands short-term tolerance. The long-term case rests on a differentiated silicon-based synthesis platform, 23.24% revenue growth, gross margin expansion of roughly 760bps since Q4 2024, and a balance sheet with a 3.64 current ratio that funds about 14 quarters of current burn — but the company is still unprofitable with a -20.6% net margin and pays no dividend, so returns depend entirely on the growth bridge to $1.011 billion being delivered. The short-term reality is brutal: beta of 2.222, a -41.17% max drawdown, a 15.3% one-month decline, and a 12.0% single-day rebound on 2026-11-09 that suggests short covering rather than accumulation. A concrete minimum holding period of 18-24 months is appropriate, spanning at least two to three more earnings cycles so the TuneLab economics and the cash-burn trajectory can be observed, and positions should be sized so that a 40% drawdown is survivable rather than portfolio-threatening.